Trial
NCT01247922
Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
OSI Pharmaceuticals
Collaborators
—
Condition
Ependymoma
Intervention
Erlotinib
Why stopped
In a pre-planned interim analysis, OSI-774-205 met futility for efficacy with no safety concerns. As a result, the companion trial, OSI-774-206 has been stopped
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-12-06